Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 2
2011 1
2012 2
2014 2
2015 7
2016 4
2017 15
2018 14
2019 12
2020 21
2021 28
2022 16
2023 17
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Results by year

Filters applied: . Clear all
Page 1
Liquid biopsy: current technology and clinical applications.
Nikanjam M, Kato S, Kurzrock R. Nikanjam M, et al. Among authors: kato s. J Hematol Oncol. 2022 Sep 12;15(1):131. doi: 10.1186/s13045-022-01351-y. J Hematol Oncol. 2022. PMID: 36096847 Free PMC article. Review.
Targeting ARID1A mutations in cancer.
Mullen J, Kato S, Sicklick JK, Kurzrock R. Mullen J, et al. Among authors: kato s. Cancer Treat Rev. 2021 Nov;100:102287. doi: 10.1016/j.ctrv.2021.102287. Epub 2021 Sep 6. Cancer Treat Rev. 2021. PMID: 34619527 Review.
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.
Fujiwara Y, Kato S, Nesline MK, Conroy JM, DePietro P, Pabla S, Kurzrock R. Fujiwara Y, et al. Among authors: kato s. Cancer Treat Rev. 2022 Nov;110:102461. doi: 10.1016/j.ctrv.2022.102461. Epub 2022 Aug 30. Cancer Treat Rev. 2022. PMID: 36058143 Free article. Review.
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.
Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R. Sicklick JK, et al. Among authors: kato s. Nat Med. 2019 May;25(5):744-750. doi: 10.1038/s41591-019-0407-5. Epub 2019 Apr 22. Nat Med. 2019. PMID: 31011206 Free PMC article. Clinical Trial.
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.
de Braud F, Dooms C, Heist RS, Lebbe C, Wermke M, Gazzah A, Schadendorf D, Rutkowski P, Wolf J, Ascierto PA, Gil-Bazo I, Kato S, Wolodarski M, McKean M, Muñoz Couselo E, Sebastian M, Santoro A, Cooke V, Manganelli L, Wan K, Gaur A, Kim J, Caponigro G, Couillebault XM, Evans H, Campbell CD, Basu S, Moschetta M, Daud A. de Braud F, et al. Among authors: kato s. J Clin Oncol. 2023 May 10;41(14):2651-2660. doi: 10.1200/JCO.22.02018. Epub 2023 Mar 22. J Clin Oncol. 2023. PMID: 36947734 Clinical Trial.
ALK fusions in the pan-cancer setting: another tumor-agnostic target?
Shreenivas A, Janku F, Gouda MA, Chen HZ, George B, Kato S, Kurzrock R. Shreenivas A, et al. Among authors: kato s. NPJ Precis Oncol. 2023 Sep 29;7(1):101. doi: 10.1038/s41698-023-00449-x. NPJ Precis Oncol. 2023. PMID: 37773318 Free PMC article. Review.
134 results